DOCSLIB.ORG

3399-3406-Aparna Natarajan-Suppl 8.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

SUPPLEMENTARY TABLE S4 B Cmap results- drug list of Set B CML PRIOR TREATMENT BONE MARROW VS CML POST TREATMENT BONE MARROW -Set B CMap rank batch cmap name dose cell score up down instance_id 1 664 alprostadil 11 µM HL60 1 0.27 -0.189 2938 2 618 mebendazole 14 µM HL60 0.916 0.272 -0.148 2338 3 634 puromycin 7 µM HL60 0.907 0.277 -0.14 2448 4 623 colchicine 10 µM HL60 0.905 0.261 -0.154 1598 5 665 quinpirole 16 µM HL60 0.904 0.287 -0.128 2977 6 749 (-)-isoprenaline 16 µM HL60 0.882 0.256 -0.149 6149 7 645 gossypol 8 µM HL60 0.861 0.228 -0.168 2202 8 602 tanespimycin 1 µM HL60 0.861 0.296 -0.099 1167 9 602 monorden 100 nM HL60 0.851 0.273 -0.117 1160 10 602 tretinoin 1 µM HL60 0.85 0.242 -0.149 1152 11 645 lycorine 12 µM HL60 0.846 0.251 -0.137 2195 12 630 anisomycin 15 µM HL60 0.83 0.262 -0.119 1304 13 623 methylergometrine 9 µM HL60 0.828 0.232 -0.149 1607 14 634 menadione 23 µM HL60 0.813 0.215 -0.158 2439 15 644 co-dergocrine mesilate 6 µM HL60 0.81 0.195 -0.177 2136 16 640 dihydroergocristine 6 µM HL60 0.785 0.229 -0.132 1745 17 602 thioridazine 10 µM HL60 0.781 0.242 -0.116 1171 18 650 thioridazine 10 µM HL60 0.779 0.216 -0.142 2690 19 623 etoposide 7 µM HL60 0.776 0.207 -0.149 1626 20 635 orciprenaline 8 µM HL60 0.771 0.194 -0.16 2485 21 644 emetine 7 µM HL60 0.77 0.211 -0.143 2145 22 602 LY-294002 10 µM HL60 0.761 0.206 -0.144 1177 23 634 cephaeline 6 µM HL60 0.758 0.209 -0.139 2429 24 641 (+)-chelidonine 11 µM HL60 0.75 0.264 -0.081 1786 25 602 tanespimycin 1 µM HL60 0.745 0.237 -0.105 1166 26 750 tanespimycin 1 µM HL60 0.735 0.235 -0.103 6185 27 613 bromocriptine 5 µM HL60 0.732 0.205 -0.131 2007 28 645 helveticoside 7 µM HL60 0.732 0.211 -0.125 2192 29 619 pergolide 10 µM HL60 0.727 0.199 -0.135 2403 30 634 dinoprost 8 µM HL60 0.723 0.241 -0.091 2446 31 651 isoetarine 12 µM HL60 0.718 0.21 -0.12 2711 32 612 niclosamide 12 µM HL60 0.715 0.164 -0.164 1998 33 602 sirolimus 100 nM HL60 0.712 0.186 -0.141 1162 34 750 15-delta prostaglandin J2 10 µM HL60 0.692 0.175 -0.143 6190 35 629 betazole 27 µM HL60 0.692 0.168 -0.15 1854 36 657 parthenolide 16 µM MCF7 0.692 0.146 -0.172 2885 37 614 dihydroergotamine 3 µM HL60 0.689 0.165 -0.151 1398 38 603 prochlorperazine 10 µM PC3 0.687 0.147 -0.168 1215 39 650 geldanamycin 1 µM HL60 0.686 0.221 -0.094 2688 40 661 Prestwick-983 17 µM HL60 0.686 0.225 -0.09 3141 41 612 thioridazine 10 µM HL60 0.686 0.222 -0.093 1986 42 623 clenbuterol 13 µM HL60 0.677 0.205 -0.106 1613 43 614 terfenadine 8 µM HL60 0.677 0.199 -0.112 1381 44 602 geldanamycin 1 µM HL60 0.674 0.167 -0.142 1169 45 622 etacrynic acid 13 µM HL60 0.673 0.18 -0.128 1565 46 650 tretinoin 1 µM HL60 0.67 0.151 -0.156 2671 47 750 thioridazine 10 µM HL60 0.669 0.193 -0.115 6189 48 640 prenylamine 10 µM HL60 0.668 0.194 -0.112 1737 49 733 strophanthidin 10 µM PC3 0.667 0.208 -0.098 5826 50 651 corbadrine 22 µM HL60 0.664 0.211 -0.094 2710 51 617 chlorphenesin 16 µM PC3 0.663 0.136 -0.169 2115 52 602 sirolimus 100 nM HL60 0.661 0.147 -0.157 1148 53 651 cicloheximide 14 µM HL60 0.66 0.212 -0.091 2723 54 619 perhexiline 10 µM HL60 0.659 0.184 -0.119 2410 55 650 tanespimycin 1 µM HL60 0.658 0.208 -0.094 2666 56 630 suloctidil 12 µM HL60 0.657 0.162 -0.14 1297 57 645 lanatoside C 4 µM HL60 0.656 0.19 -0.111 2193 58 602 tanespimycin 1 µM HL60 0.648 0.162 -0.136 1159 59 750 LY-294002 10 µM HL60 0.647 0.176 -0.121 6195 60 650 tanespimycin 1 µM HL60 0.647 0.182 -0.115 2678 61 650 prochlorperazine 10 µM HL60 0.646 0.17 -0.127 2675 62 603 thioridazine 10 µM PC3 0.645 0.121 -0.175 1230 63 610 thioridazine 10 µM PC3 0.643 0.13 -0.166 1905 64 506 15-delta prostaglandin J2 10 µM MCF7 0.641 0.156 -0.139 1011 65 750 tanespimycin 1 µM HL60 0.64 0.189 -0.104 6184 66 603 trifluoperazine 10 µM PC3 0.639 0.096 -0.197 1224 67 622 tretinoin 13 µM HL60 0.639 0.174 -0.119 1548 68 602 15-delta prostaglandin J2 10 µM HL60 0.634 0.171 -0.12 1172 69 619 isotretinoin 13 µM HL60 0.633 0.195 -0.095 2407 70 630 bepridil 10 µM HL60 0.633 0.134 -0.157 1274 71 749 oxedrine 24 µM HL60 0.632 0.202 -0.088 6156 72 702 methylbenzethonium 9 µM PC3 0.628 0.194 -0.094 4325 chloride 73 623 cefoperazone 6 µM HL60 0.628 0.184 -0.104 1627 74 626 15-delta prostaglandin J2 10 µM MCF7 0.627 0.119 -0.169 1656 75 623 metitepine 8 µM HL60 0.625 0.129 -0.158 1616 76 602 LY-294002 10 µM HL60 0.624 0.136 -0.151 1168 77 634 ciclopirox 15 µM HL60 0.622 0.187 -0.098 2456 78 1069 MG-262 100 nM PC3 0.621 0.145 -0.141 7068 79 660 tonzonium bromide 7 µM HL60 0.618 0.177 -0.107 3080 80 628 chlorpromazine 11 µM PC3 0.617 0.169 -0.114 1822 81 618 salbutamol 17 µM HL60 0.616 0.153 -0.13 2344 82 623 adenosine phosphate 11 µM HL60 0.613 0.187 -0.094 1622 83 686 helveticoside 7 µM MCF7 0.612 0.158 -0.123 3851 84 634 amphotericin B 4 µM HL60 0.609 0.184 -0.095 2441 85 75 1,5-isoquinolinediol 100 µM HL60 0.608 0.193 -0.086 543 86 650 tanespimycin 1 µM HL60 0.608 0.208 -0.071 2686 87 648 strophanthidin 10 µM HL60 0.606 0.194 -0.084 2525 88 602 fluphenazine 10 µM HL60 0.605 0.187 -0.091 1178 89 1073 MG-262 100 nM PC3 0.605 0.135 -0.142 7079 90 753 azacyclonol 15 µM PC3 0.604 0.064 -0.213 6298 91 686 citiolone 25 µM MCF7 0.603 0.157 -0.12 3836 92 619 minocycline 8 µM HL60 0.602 0.118 -0.158 2405 93 623 dobutamine 12 µM HL60 0.601 0.17 -0.106 1589 94 734 alimemazine 5 µM PC3 0.601 0.092 -0.184 5881 95 659 (+)-isoprenaline 11 µM HL60 0.601 0.139 -0.137 3046 96 514 MG-132 21 µM MCF7 0.601 0.148 -0.128 1140 97 614 dexamethasone 9 µM HL60 0.599 0.113 -0.162 1396 98 729 puromycin 7 µM MCF7 0.599 0.121 -0.154 5310 99 623 ketanserin 7 µM HL60 0.599 0.166 -0.109 1593 100 664 meptazinol 15 µM HL60 0.597 0.114 -0.16 2906 101 649 mephentermine 9 µM HL60 0.597 0.191 -0.083 2563 102 686 lanatoside C 4 µM MCF7 0.596 0.172 -0.102 3852 103 75 gefitinib 10 µM HL60 0.595 0.15 -0.123 541 104 664 trichostatin A 100 nM HL60 0.595 0.161 -0.112 2904 105 677 pyrvinium 3 µM MCF7 0.591 0.158 -0.113 3518 106 754 pyrvinium 3 µM PC3 0.59 0.115 -0.156 6339 107 701 foliosidine 13 µM PC3 0.589 0.127 -0.144 4295 108 602 LY-294002 10 µM HL60 0.589 0.178 -0.093 1180 109 631 digitoxigenin 11 µM HL60 0.589 0.169 -0.102 1339 110 718 chlorpromazine 11 µM PC3 0.589 0.146 -0.125 5074 111 750 tanespimycin 1 µM HL60 0.587 0.156 -0.113 6166 112 623 trichostatin A 100 nM HL60 0.587 0.117 -0.152 1612 113 650 15-delta prostaglandin J2 10 µM HL60 0.584 0.179 -0.089 2691 114 603 tanespimycin 1 µM PC3 0.582 0.087 -0.18 1225 115 631 bacampicillin 8 µM HL60 0.581 0.159 -0.108 1337 116 630 ouabain 5 µM HL60 0.58 0.172 -0.095 1302 117 622 albendazole 15 µM HL60 0.58 0.161 -0.105 1547 118 640 lobelanidine 11 µM HL60 0.58 0.184 -0.082 1747 119 686 flecainide 8 µM MCF7 0.578 0.155 -0.111 3843 120 502 pyrvinium 1 µM MCF7 0.578 0.069 -0.197 978 121 686 pempidine 13 µM MCF7 0.576 0.136 -0.128 3832 122 714 desipramine 13 µM PC3 0.574 0.129 -0.134 6693 123 765 15-delta prostaglandin J2 10 µM MCF7 0.573 0.146 -0.117 6990 124 648 terazosin 9 µM HL60 0.573 0.181 -0.081 2530 125 714 profenamine 11 µM PC3 0.572 0.121 -0.142 6697 126 707 ouabain 5 µM MCF7 0.572 0.132 -0.13 5026 127 640 ceftazidime 6 µM HL60 0.571 0.128 -0.134 1721 128 1052 trichostatin A 1 µM PC3 0.568 0.124 -0.137 6886 129 617 etofylline 18 µM PC3 0.568 0.092 -0.168 2093 130 657 prenylamine 10 µM MCF7 0.567 0.109 -0.151 2886 131 648 tetryzoline 17 µM HL60 0.567 0.123 -0.137 2507 132 718 pizotifen 9 µM PC3 0.566 0.151 -0.109 5072 133 706 lasalocid 7 µM MCF7 0.566 0.135 -0.125 4985 134 502 5252917 14 µM MCF7 0.566 0.092 -0.168 944 135 727 thioridazine 10 µM PC3 0.566 0.175 -0.084 4454 136 626 thioridazine 10 µM MCF7 0.565 0.148 -0.111 1655 137 513 geldanamycin 1 µM MCF7 0.564 0.114 -0.145 1066 138 612 trichostatin A 100 nM HL60 0.564 0.162 -0.097 1971 139 626 trifluoperazine 10 µM MCF7 0.563 0.118 -0.141 1649 140 725 alvespimycin 100 nM MCF7 0.562 0.176 -0.082 5210 141 710 ouabain 5 µM PC3 0.562 0.196 -0.062 6680 142 603 fluphenazine 10 µM PC3 0.559 0.098 -0.159 1237 143 728 clomipramine 11 µM PC3 0.559 0.08 -0.177 4487 144 657 mometasone 8 µM MCF7 0.558 0.09 -0.166 2896 145 502 rottlerin 10 µM MCF7 0.556 0.114 -0.142 941 146 730 digoxin 5 µM MCF7 0.556 0.135 -0.12 5324 147 714 loxapine 9 µM PC3 0.556 0.163 -0.093 6694 148 731 cicloheximide 14 µM PC3 0.555 0.138 -0.117 5743 149 732 spiperone 10 µM PC3 0.554 0.138 -0.116 5777 150 506 tanespimycin 1 µM MCF7 0.554 0.121 -0.133 998 151 618 kawain 17 µM HL60 0.552 0.141 -0.113 2337 152 712 bepridil 10 µM PC3 0.552 0.079 -0.174 4613 153 603 LY-294002 10 µM PC3 0.552 0.065 -0.189 1227 154 641 vinburnine 14 µM HL60 0.552 0.168 -0.085 1788 155 650 trifluoperazine 10 µM HL60 0.552 0.174 -0.079 2684 156 750 sirolimus 100 nM HL60 0.552 0.133 -0.121 6180 157 1032 5155877 10 µM PC3 0.551 0.088 -0.165 6544 158 623 probucol 8 µM HL60 0.55 0.145 -0.107 1608 159 714 chlorprothixene 11 µM PC3 0.55 0.083 -0.169 6692 160 727 sirolimus 100 nM PC3 0.55 0.149 -0.103 4445 161 698 0175029-0000 1 µM PC3 0.55 0.095 -0.158 7392 162 665 S-propranolol 14 µM HL60 0.549 0.124 -0.128 2961 163 732 mianserin 13 µM PC3 0.549 0.133 -0.119 5786 164 727 alvespimycin 100 nM PC3 0.548 0.126 -0.125 4437 165 656 thiostrepton 2 µM MCF7 0.548 0.095 -0.156 2823 166 686 ethoxyquin 18 µM MCF7 0.547 0.179 -0.073 3846 167 622 clonidine 15 µM HL60 0.547 0.141 -0.11 1555 168 651 securinine 18 µM HL60 0.547 0.113 -0.138 2729 169 626 tanespimycin 1 µM MCF7 0.546 0.14 -0.111 1643 170 502 wortmannin 1 µM MCF7 0.545 0.102 -0.148 977 171 664 harpagoside 8 µM HL60 0.545 0.135 -0.115 2935 172 703 withaferin A 1 µM PC3 0.545 0.094 -0.157 4554 173 502 monorden 100 nM MCF7 0.545 0.113 -0.137 953 174 762 homochlorcyclizine
Recommended publications
  • ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0

    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0

    ELECTRONIC CLAIMS MANAGEMENT ENGINE (ECME) Version 1.0 USER MANUAL December 2020 Department of Veterans Affairs Office of Information and Technology (OIT) Product Development Revision History Date Description (Patch # if applicable) Project Manager Technical Writer 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx Claims Report ePharmacy ePharmacy Screen Display Development TeamDevelopment Team Updated Title Page date and footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx. 05/2017 Updated for BPS*1*21 REDACTED REDACTED 08/2016 Updated for BPS*1*20 REDACTED
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of Peroxisome Proliferator-Activated Receptor-Α And

    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
  • Genl:VE 1970 © World Health Organization 1970

    Genl:VE 1970 © World Health Organization 1970

    Nathan B. Eddy, Hans Friebel, Klaus-Jiirgen Hahn & Hans Halbach WORLD HEALTH ORGANIZATION ORGANISATION .MONDIALE DE LA SANT~ GENl:VE 1970 © World Health Organization 1970 Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization. For rights of reproduction or translation of WHO publications in toto, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications. Authors alone are responsible for views expressed in signed articles. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. © Organisation mondiale de la Sante 1970 Les publications de l'Organisation mondiale de la Sante beneficient de la protection prevue par les dispositions du Protocole n° 2 de la Convention universelle pour la Protection du Droit d'Auteur. Les institutions gouvernementales et les societes savantes ou professionnelles peuvent, toutefois, reproduire des donnees, des extraits ou des illustrations provenant de ces publications, sans en demander l'autorisation a l'Organisation mondiale de la Sante. Pour toute reproduction ou traduction integrate, une autorisation doit etre demandee a la Division des Services d'Edition et de Documentation, Organisation mondiale de la Sante, Geneve, Suisse.
  • Electronic Claims Management Version 1.0 Engine User Manual

    Electronic Claims Management Version 1.0 Engine User Manual

    Electronic Claims Management Engine (ECME) Version 1.0 User Manual May 2021 Department of Veterans Affairs Office of Information and Technology (OIT) Revision History Description (Patch # if Date Project Manager Technical Writer applicable) 05/2021 Updated for BPS*1*28 MCCF EDI TAS MCCF EDI TAS Updated Title Page date and ePharmacy ePharmacy footers Development Development Added Section 6.3.3 SC Team Team Prescriptions for Active Duty Prescriptions Added Section 8.1.11 Duplicate Claims Report 12/2020 Updated for BPS*1*27 MCCF EDI TAS MCCF EDI TAS Updated Potential Secondary Rx ePharmacy ePharmacy Claims Report Screen Display Development Development Updated Title Page date and Team Team footers 04/2020 Updated for BPS*1*26 REDACTED REDACTED Updated section 5.6 Add/View Comments Updated Title Page date and footers 1/2019 Updated for BPS*1*24 REDACTED REDACTED Change label on Claim Log, Modify Change View (CV), Enhance Claim Reports 08/2018 Updated for BPS*1*23 REDACTED REDACTED Update Title page date, footer date Modification filter questions CV Change View action, Rx Activity Log to add Date of Service to ECME Log, Resubmit with Edits action, Process Secondary/TRICARE Rx to ECME option, Payable Claims Report, Rejected Claims Report, Reversal Claims Report, Claims Submitted Not Yet Released Report, Recent Transactions Report, Closed Claims Report, View ePharmacy Rx Report Option Electronic Claims Management Engine V. 1.0 User Manual ii May 2021 Description (Patch # if Date Project Manager Technical Writer applicable) 11/2017 Updated for BPS*1*22 REDACTED REDACTED Update Title page date, modification to Change View action; change auto-reverse parameter and auto-reversal bulletin; add Facility ID Qualifier and Reconciliation ID to Claim Log and Claim Response Inquiry; add new action PR Print Reports to VER View ePharmacy Rx.
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1

    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
  • 2011/058582 Al O

    2011/058582 Al O

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date i 1 m 19 May 2011 (19.05.2011) 2011/058582 Al (51) International Patent Classification: Road, Sholinganallur, Chennai 600 119 (IN). CHEN- C07C 259/06 (2006.01) A61P 31/00 (2006.01) NIAPPAN, Vinoth Kumar [IN/IN]; Orchid Research C07D 277/46 (2006.01) A61K 31/426 (2006.01) Laboratories Ltd., R & D Centre: Plot No: 476/14, Old C07D 277/48 (2006.01) A61K 31/55 (2006.01) Mahabalipuram Road, Sholinganallur, Chennai 600 119 C07D 487/08 (2006.01) (IN). GANESAN, Karthikeyan [IN/IN]; Orchid Re search Laboratories Ltd., R & D Centre: Plot No: 476/14, (21) International Application Number: Old Mahabalipuram Road, Sholinganallur, Chennai 600 PCT/IN20 10/000738 119 (IN). NARAYANAN, Shridhar [IN/IN]; Orchid Re (22) International Filing Date: search Laboratories Ltd., R & D Centre: Plot No: 476/14, 12 November 2010 (12.1 1.2010) Old Mahabalipuram Road, Sholinganallur, Chennai 600 119 (IN). (25) Filing Language: English (74) Agent: UDAYAMPALAYAM PALANISAMY, (26) Publication Language: English Senthilkumar; Orchid Chemicals & Pharmaceuticals (30) Priority Data: LTD., R & D Centre: Plot No: 476/14, Old Mahabalipu 2810/CHE/2009 16 November 2009 (16. 11.2009) IN ram Road, Sholinganallur, Chennai 600 119 (IN). (71) Applicant (for all designated States except US): OR¬ (81) Designated States (unless otherwise indicated, for every CHID RESEARCH LABORATORIES LTD. [IN/IN]; kind of national protection available): AE, AG, AL, AM, Orchid Towers, 313, Valluvar Kottam High Road, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, Nungambakkam, Chennai 600 034 (IN).
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives

    Sympathoadrenergic Modulation of Hematopoiesis: a Review of Available Evidence and of Therapeutic Perspectives

    REVIEW published: 05 August 2015 doi: 10.3389/fncel.2015.00302 Sympathoadrenergic modulation of hematopoiesis: a review of available evidence and of therapeutic perspectives Marco Cosentino*, Franca Marino and Georges J. M. Maestroni Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy Innervation of the bone marrow (BM) has been described more than one century ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in hematopoiesis dates back to less than 25 years ago. Evidence has since increased showing that adrenergic nerves in the BM release noradrenaline and possibly also dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed on hematopoietic cells and affect cell survival, proliferation, migration and engraftment ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with hematopoietic disturbances and myeloproliferative disease. Several adrenergic and dopaminergic agents are already in clinical use for non-hematological indications and with a usually favorable risk-benefit profile, and are therefore potential candidates for Edited by: non-conventional modulation of hematopoiesis. Wanda Lattanzi, Università Cattolica del Sacro Cuore, Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis, Italy neuroimmune phamacology, drug repurposing Reviewed by: Sujit Basu, Introduction Ohio State University, USA Tsvee Lapidot, Weizmann Institute of Science, Israel The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to designate a shallow recess in a wall, as for a statue or other decorative object, in view of the *Correspondence: similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or Marco Cosentino, Center for Research in Medical thing.
  • Microspore Embryogenesis: Targeting the Determinant Factors of Stress- Induced Cell Reprogramming for Crop Improvement

    Microspore Embryogenesis: Targeting the Determinant Factors of Stress- Induced Cell Reprogramming for Crop Improvement

    1 2 3 4 Microspore embryogenesis: targeting the determinant factors of stress- 5 induced cell reprogramming for crop improvement 6 7 8 Pilar S. Testillano 9 10 Pollen Biotechnolgy of Crop Plants group. Biological Research Center, CIB-CSIC. 11 Ramiro de Maeztu 9, 28040 Madrid. Spain 12 E-mail: [email protected] 13 Phone: +34-918373112 (Ext: 4366) 14 15 Date of submission: October 31, 2018 16 Number of figures: 5. 17 Word count: 6312. 18 19 Running title: 20 Determinant factors of stress-induced microspore embryogenesis in crops 1 21 ABSTRACT 22 23 Under stress, isolated microspores are reprogrammed in vitro towards embryogenesis, 24 producing doubled haploid plants, useful biotechnological tools in plant breeding as a 25 source of new genetic variability, fixed in homozygous plants in only one generation. 26 Stress-induced cell death and low rates of cell reprogramming are major factors that 27 reduce the process yield. Knowledge gained in recent years has revealed that 28 microspore embryogenesis initiation and progression involve a complex network of 29 factors, whose roles are not yet well understood. Autophagy and cell-death proteases are 30 crucial players in the response to stress, while cell reprogramming and totipotency 31 acquisition are regulated by hormonal and epigenetic mechanisms. Auxin biosynthesis, 32 transport and action are required for microspore embryogenesis. Initial stages involve 33 DNA hypomethylation, H3K9 demethylation, and H3/H4 acetylation. Cell wall 34 remodelling, with pectin de-methylesterification and AGP expression, is necessary for 35 embryo development. We will review recent findings regarding the determinant factors 36 underlying stress-induced microspore embryogenesis, focusing on the role of 37 autophagy, cell death, auxin, chromatin modifications, and cell wall.
  • Epigenetic Malleability at Core Promoter Regulates Tobacco PR-1A

    Epigenetic Malleability at Core Promoter Regulates Tobacco PR-1A

    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.24.453639; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Research article: 2 Epigenetic Malleability at Core Promoter Regulates Tobacco PR-1a 3 Expression after Salicylic Acid Treatment 4 5 Authors: Niraj Lodhi1*, Mala Singh1, Rakesh Srivastava1, Samir V. Sawant1, and Rakesh 6 Tuli1,3 7 8 1. National Botanical Research Institute, Council of Scientific and Industrial Research, Rana 9 Pratap Marg, Lucknow-226001, India 10 2. Present address: University Institute of Engineering & Technology (UIET), Sector 25, 11 Panjab University, Chandigarh 160014, India 12 13 14 *Corresponding Author: 15 Niraj Lodhi, Ph.D. 16 Lead, Clinical Research (Research and Development Division) 17 Genesis DiaGnostics 18 LanGhorne, PA 19047 19 Ph: 267-212-2000 Ext. 156 20 Fax: 267-212-2005 21 E-mail: [email protected] 22 23 24 25 SUMMARY 26 Histone methylation and acetylation regulation of tobacco PR-1a promoter are significant for 27 disassembly of the nucleosome and repressor proteins during induction. 28 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.07.24.453639; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 29 ABSTRACT 30 • Tobacco’s PR-1a gene is induced by pathogen attack or exogenous application of 31 Salicylic Acid (SA). However, the epigenetic modifications of the most important 32 inducible promoter of the PR-1a gene are not understood clearly.
  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
  • (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al

    (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle Et Al

    USOO9376418B2 (12) United States Patent (10) Patent No.: US 9,376.418 B2 Haidle et al. (45) Date of Patent: Jun. 28, 2016 (54) SUBSTITUTED PYRIDINE SPLEEN 31/5377 (2013.01); A61K3I/5383 (2013.01); TYROSINE KINASE (SYK) INHIBITORS A61 K3I/551 (2013.01); A61K 45/06 (2013.01); C07D401/14 (2013.01); C07D (71) Applicants: Merck Sharp & Dohme Corp., 405/14 (2013.01); C07D 409/14 (2013.01); Rahway, NJ (US); Merck Canada Inc., C07D 413/14 (2013.01); C07D 417/14 Kirkland, Quebec (CA) (2013.01); C07D 471/04 (2013.01); (Continued) Inventors: (72) Andrew M. Haidle, Cambridge, MA (58) Field of Classification Search (US); Sandra Lee Knowles, Princeton, CPC ............... CO7D 401/12: CO7D 401/14: A61 K NJ (US); Solomon D. Kattar, Arlington, 31/5377; A61K31/506 MA (US); Denis Deschenes, Lachine USPC ........................ 544/122, 331; 514/235.8, 275 (CA); Jason Burch, Redwood City, CA See application file for complete search history. (US); Joel Robichaud, Dollard-des-Ormeaux (CA); Matthew (56) References Cited Christopher, Brookline, MA (US); Michael D. Altman, Needham, MA U.S. PATENT DOCUMENTS (US); James P. Jewell, Newtown, MA 5,710,129 A 1/1998 Lynch et al. (US); Alan B. Northrup, Reading, VA 6/2001 Uckun et al. (US); Marc Blouin, Saint-Lazare (CA); 6,248,790 B1 John Michael Ellis, Needham, MA (Continued) (US); Hua Zhou, Acton, MA (US); Christian Fischer, Natick, MA (US); FOREIGN PATENT DOCUMENTS Adam J. Schell, Decatur, GA (US); EP 877O2O A1 11, 1998 Michael H. Reutershan, Brookline, MA EP 2441755 A1 4/2012 (US); Brandon M.